摘要
目的观察补肾生血方联合司坦唑醇治疗慢性再生障碍性贫血(CAA)的临床疗效及其与外周血T淋巴细胞亚群的关系。方法将60例CAA患者随机分为实验组和对照组、每组各30例,另设空白对照组20例。实验组给予补肾生血方加司坦唑醇口服治疗,对照组给予司坦唑醇口服治疗。检测实验组、对照组治疗前、治疗后9个月以及空白对照组外周血T淋巴细胞亚群。结果 (1)实验组治疗总有效率为86.67%,优于对照组的63.33%,差异有统计学意义(P<0.05);(2)CAA患者治疗前CD4+、CD8+、CD4+/CD8+,CD4+CD45RA+、CD4+CD45RO+、CD8+CD45RO+的表达与空白对照组比较有统计学差异(P<0.05);CD3+、CD8+CD45RA+的表达两者间无差异(P>0.05);(3)实验组治疗前后CD3+、CD4+、CD8+、CD4+/CD8+、CD4+CD45RA+、CD4+CD45RO+、CD8+CD45RO+比较差异有统计学意义(P<0.05);而CD8+CD45RA+差异无统计学意义(P>0.05);(4)实验组与对照组治疗后CD4+、CD8+、CD4+CD45RA+、CD4+CD45RO+比较差异有统计学意义(P<0.05),而CD3+、CD4+、CD8+、CD8+CD45RA+、CD8+CD45RO+比较差异无统计学意义(P>0.05)。结论补肾生血方联合司坦唑醇治疗CAA疗效显著,并且在改善患者外周血淋巴细胞亚群方面能体现出明显优势。
Objective To observe the therapeutic effect of kidney-tonifying and blood-engendering compound（ KBC） on chronic aplastic anemia（ CAA） and the relationship with lymphocyte subsets in peripheral blood. Methods Sixty CAA patients were randomized into trial group（ n = 30） and control group（ n = 30）. A healthy blank group consisting of healthy people（ n = 20） were also set up. The control group was treated with stanozolol and the trial group additionally with KBC. Their peripheral T lymphocyte subsets were measured before and after treatment. Results（ 1） The total efficiency of the trial group was 86. 67%,significantly higher than that（ 73. 33%） of the control group.（ 2） Before treatment,the differences in the expressions of CD4＋,CD8＋,CD4＋/ CD8＋,CD4＋CD45RA＋,CD4＋CD45RO＋and CD8＋CD45RO＋were significant between any of the two CAA groups and the healthy blank group（ P〈0. 05）; the differences in the expressions of CD3＋and CD8＋CD45RA＋were not significant（ P〉0. 05）.（ 3） In the trial group,the differences in CD3＋,CD4＋,CD8＋,CD4＋/ CD8＋,CD4＋CD45RA＋,CD4＋CD45RO＋and CD8＋CD45RO＋were significant between before and after treatment（ P〈0. 05）; the difference in CD8＋CD45RA＋was not significant（ P〉0. 05）.（ 4） Between the trial group and the control group,the differences in CD4＋,CD8＋,CD4＋CD45RA＋and CD4＋CD45RO＋were significant after treatment（ P〈0. 05）; the differences in CD3＋,CD4＋/ CD8＋,CD8＋CD45RA＋and CD8＋CD45RO＋were not signifi（ P〉0. 05）. Conclusion KBC,in combination with stanozolol,is therapeutically effective on CAA.
出处
《临床军医杂志》
CAS
2015年第5期469-471,共3页
Clinical Journal of Medical Officers
基金
大连市科技计划项目[大卫科发(2010)153号]
关键词
慢性再生障碍性贫血
补肾生血方
可坦唑醇
Chronic aplastic anemia
Kidney-tonifying and blood-engendering compound
Stanozolol
